The availability of five insulin glargine products as multiple presentations in the UK market creates a real potential for confusion in the prescribing, dispensing, and administration of these products. This review summarises safety considerations associated with the use of high strength glargine products and the biosimilars.
The UKMI product safety assessment group would appreciate your views on the usefulness of this assessment. We have devised a short survey which we would appreciate you completing, it should take approximately 10 minutes to complete. Click here – https://www.surveymonkey.com/r/UKMiProductSafetyAssessments – to complete the survey.